University of California San Francisco
Give to UCSFMany patients with COVID-19 develop brain fog and other cognitive symptoms months later. Their cerebrospinal fluid may hold clues to why this is happening.
In the quest for new treatments for COVID-19, a team led by UCSF researchers identified a new potential drug target that may prevent infection of human cells by SARS-CoV-2.
A new study led by scientists at UCSF's Quantitative Biosciences Institute and University College London found that the Alpha variant of SARS-CoV-2 ramped up production of a protein that it uses to stifle infected cells’ immune-stimulating signals, helping it evade immune detection and accelerate its transmission.
There is some information that is known about the variant and other information that sti
Monica Gandhi, MD, MPH, an infectious disease expert and professor of medicine, has been an ardent voice for science during the coronavirus pandemic.
A concerted research effort gave UCSF scientists early insight into long COVID. It also showed patients that they weren’t in the fight alone.
Since the early months of the pandemic, physicians throughout UCSF have pitched in to help support hundreds of long COVID patients.
A UCSF and Stanford study of electronic health records linked SSRIs, the most widely prescribed antidepressants, to survival for COVID-19 patients.
UCSF’s research has been ranked among the top in the world, according to the latest U.S. News & World Report’s Best Global Universities 2022 rankings.